Overview Dividends

(BBIO) BridgeBio Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US10806X1028

ATTR Medication, FGFR Inhibitor, CaSR Antagonist, Muscular Dystrophy Therapy, Oncology Pipeline

BBIO EPS (Earnings per Share)

EPS Growth (3Y CAGR): 12.17%
EPS Trend (3Y Correlation): 3.0%

BBIO Revenue

Revenue Growth (3Y CAGR): 355.13%
Revenue Trend (3Y Correlation): 69.8%

Description: BBIO BridgeBio Pharma November 04, 2025

BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma focused on developing small-molecule and gene-therapy treatments for rare genetic diseases and oncology indications.

Its pipeline includes:

Attruby – an oral transthyretin (TTR) stabilizer in late-stage development for ATTR-CM, a progressive amyloidosis affecting the heart.
Low-dose infigratinib – an FGFR1-3 selective tyrosine-kinase inhibitor being evaluated in a Phase 3 double-blind trial for achondroplasia and in a Phase 2/3 study for hypochondroplasia.
Encaleret – a calcium-sensing-receptor antagonist in Phase 3 for autosomal-dominant hypocalcemia type 1 (ADH1).
BBP-418 – a glycosylation-substrate pro-drug in Phase 3 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

BridgeBio also pursues programs in Mendelian genetics, oncology, and gene-therapy platforms, leveraging collaborations with Alexion, Stanford, Leidos Biomedical, and Novartis.

Key recent metrics (as of Q3 2024): market capitalization ≈ $2.3 B, cash and equivalents of $550 M providing ~18 months of runway at current burn, and a 2023-2024 revenue run-rate of $120 M driven primarily by Attruby sales in Europe.

Sector-wide, the rare-disease biotech market is expanding at a CAGR of ~12 % (2022-2027) as payer frameworks increasingly accommodate high-price, high-impact therapies, which underpins BridgeBio’s growth outlook.

For a deeper, data-rich evaluation of BBIO’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.

BBIO Stock Overview

Market Cap in USD	12,071m
Sub-Industry	Biotechnology
IPO / Inception	2019-06-27

BBIO Stock Ratings

Growth Rating	78.1%
Fundamental	50.7%
Dividend Rating	-
Return 12m vs S&P 500	103%
Analyst Rating	4.37 of 5

BBIO Dividends

Currently no dividends paid

BBIO Growth Ratios

Growth Correlation 3m	86.2%
Growth Correlation 12m	93.6%
Growth Correlation 5y	-7.7%
CAGR 5y	89.02%
CAGR/Max DD 3y (Calmar Ratio)	1.81
CAGR/Mean DD 3y (Pain Ratio)	4.05
Sharpe Ratio 12m	0.91
Alpha	136.16
Beta	1.363
Volatility	51.79%
Current Volume	1989.3k
Average Volume 20d	2113.7k
Stop Loss	58.5 (-4.7%)
Signal	-0.37

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-797.1m TTM) > 0 and > 6% of Revenue (6% = 21.2m TTM)

FCFTA -0.59 (>2.0%) and ΔFCFTA 9.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 176.0% (prev 140.2%; Δ 35.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.59 (>3.0%) and CFO -584.8m > Net Income -797.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (190.5m) change vs 12m ago 1.06% (target <= -2.0% for YES)

Gross Margin 95.78% (prev 98.31%; Δ -2.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 42.54% (prev 32.75%; Δ 9.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.63 (EBITDA TTM -677.3m / Interest Expense TTM 121.3m) >= 6 (WARN >= 3)

Altman Z'' -14.58

(A) 0.62 = (Total Current Assets 839.4m - Total Current Liabilities 216.6m) / Total Assets 998.2m

(B) -3.63 = Retained Earnings (Balance) -3.63b / Total Assets 998.2m

warn (B) unusual magnitude: -3.63 — check mapping/units

(D) -1.24 = Book Value of Equity -3.63b / Total Liabilities 2.92b

Total Rating: -14.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 50.66

1. Piotroski 1.0pt = -4.0

2. FCF Yield -5.15% = -2.58

3. FCF Margin data missing

4. Debt/Equity -0.00 = -2.50

5. Debt/Ebitda 0.94 = 1.85

7. RoE 46.77% = 2.50

8. Rev. Trend 69.79% = 5.23

9. EPS Trend 3.05% = 0.15

What is the price of BBIO shares?

As of November 05, 2025, the stock is trading at USD 61.37 with a total of 1,989,302 shares traded.
Over the past week, the price has changed by -4.85%, over one month by +12.38%, over three months by +28.52% and over the past year by +143.53%.

Is BridgeBio Pharma a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, BridgeBio Pharma is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 50.66 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BBIO is around 56.32 USD . This means that BBIO is currently overvalued and has a potential downside of -8.23%.

Is BBIO a buy, sell or hold?

BridgeBio Pharma has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy BBIO.

Strong Buy: 10
Buy: 6
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BBIO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	80.4	31%
Analysts Target Price	80.4	31%
ValueRay Target Price	64.2	4.6%

BBIO Fundamental Data Overview November 02, 2025

Market Cap USD = 12.07b (12.07b USD * 1.0 USD.USD)
P/S = 34.1209
P/B = 123.6828
Beta = 1.363
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.72b USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 8.72m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -634.2m USD (from netDebt column, last quarter)
Enterprise Value = 11.43b USD (12.07b + Debt 8.72m - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
FCF Yield = -5.15% (FCF TTM -589.1m / Enterprise Value 11.43b)
FCF Margin = -166.5% (FCF TTM -589.1m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 11.45 (Enterprise Value 11.43b / Total Assets 998.2m)
Interest Expense / Debt = 134.6% (Interest Expense 11.7m / Debt 8.72m)
Taxrate = 0.83% (-1.54m / -186.5m)
NOPAT = -677.0m (EBIT -682.6m * (1 - 0.83%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.00 (negative equity) (Debt 8.72m / totalStockholderEquity, last quarter -1.92b)
Debt / EBITDA = 0.94 (negative EBITDA) (Net Debt -634.2m / EBITDA -677.3m)
Debt / FCF = 1.08 (negative FCF - burning cash) (Net Debt -634.2m / FCF TTM -589.1m)
Total Stockholder Equity = -1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -79.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.77% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.70b)
RoCE = -3994 % (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.70b + L.T.Debt 1.72b))
RoIC = -394.4% (out of range, set to none) (NOPAT -677.0m / Invested Capital 171.6m)
WACC = 11.03% (E(12.07b)/V(12.08b) * Re(11.04%) + (debt cost/tax rate unavailable))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.49%
Fair Price DCF = unknown (Cash Flow -589.1m)
EPS Correlation: 3.05 | EPS CAGR: 12.17% | SUE: 0.39 | # QB: 0
Revenue Correlation: 69.79 | Revenue CAGR: 355.1% | SUE: 0.19 | # QB: 0

Additional Sources for BBIO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle